Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming

Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiov...

Full description

Saved in:
Bibliographic Details
Published inRedox biology Vol. 73; p. 103183
Main Authors Wu, Shaofa, Luo, Xiaolin, Chen, Yang, Wang, Zelan, Liu, Xi, Sun, Ning, Zhao, Junyong, Luo, Wenjian, Zhang, Jiawen, Tong, Xiaoyong, Huang, Lan, Liu, Chuan, Qin, Zhexue
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.07.2024
Elsevier
Subjects
Online AccessGet full text
ISSN2213-2317
2213-2317
DOI10.1016/j.redox.2024.103183

Cover

Abstract Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved. A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models. SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention. [Display omitted]
AbstractList Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved.AIMSVascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved.A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models.METHODS AND RESULTSA computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models.SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention.CONCLUSIONSSGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention.
Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved. A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models. SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention.
Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved. A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models. SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention. [Display omitted]
Aims: Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved. Methods and results: A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models. Conclusions: SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention.
ArticleNumber 103183
Author Liu, Chuan
Luo, Xiaolin
Qin, Zhexue
Chen, Yang
Luo, Wenjian
Wang, Zelan
Zhang, Jiawen
Wu, Shaofa
Sun, Ning
Huang, Lan
Liu, Xi
Tong, Xiaoyong
Zhao, Junyong
Author_xml – sequence: 1
  givenname: Shaofa
  surname: Wu
  fullname: Wu, Shaofa
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
– sequence: 2
  givenname: Xiaolin
  surname: Luo
  fullname: Luo, Xiaolin
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
– sequence: 3
  givenname: Yang
  surname: Chen
  fullname: Chen, Yang
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
– sequence: 4
  givenname: Zelan
  surname: Wang
  fullname: Wang, Zelan
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
– sequence: 5
  givenname: Xi
  surname: Liu
  fullname: Liu, Xi
  organization: Department of Nephrology, Youyang Hospital, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 409800, China
– sequence: 6
  givenname: Ning
  surname: Sun
  fullname: Sun, Ning
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
– sequence: 7
  givenname: Junyong
  surname: Zhao
  fullname: Zhao, Junyong
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
– sequence: 8
  givenname: Wenjian
  surname: Luo
  fullname: Luo, Wenjian
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
– sequence: 9
  givenname: Jiawen
  surname: Zhang
  fullname: Zhang, Jiawen
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
– sequence: 10
  givenname: Xiaoyong
  surname: Tong
  fullname: Tong, Xiaoyong
  organization: Innovative Drug Research Centre, Chongqing University, Chongqing, 401331, China
– sequence: 11
  givenname: Lan
  surname: Huang
  fullname: Huang, Lan
  email: huanglan260@126.com
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
– sequence: 12
  givenname: Chuan
  surname: Liu
  fullname: Liu, Chuan
  email: liuchuan19821207@163.com
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
– sequence: 13
  givenname: Zhexue
  orcidid: 0000-0001-7943-1361
  surname: Qin
  fullname: Qin, Zhexue
  email: zhexueqin@126.com
  organization: Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38759418$$D View this record in MEDLINE/PubMed
BookMark eNqNks1u1DAUhSNURMvQJ0BCXrLJYDt_9oIFqvipVIkFsLZu7JupR4kdbKcwr8bT4ZmUCrEAvLnW1fmOfO_x0-LMeYdF8ZzRLaOsfbXfBjT--5ZTXudOxUT1qLjgnFUlr1h39tv9vLiMcU_zEaLmjD4pzivRNbJm4qL48ckbu0zlbly0j0i0TwFcnH1IGAgn1t3a3iYfIoGU0C2QkNxB1MsIgWgYtR2shmS9I_2BxGWeA8Zo3Y6gM34eIU5Wk4DJZmSZyBx8QutIurX-NEK-Gz9BLtq7lOuRbYjBORugS8THhH6H7mST8V2AacqiZ8XjAcaIl_d1U3x59_bz1Yfy5uP766s3N6WuO5pKbiiABAFV3_fCcAnQNbxrJWe9QGgQ6r4G3lcoepRtrnKoqQbZZ55rUW2K69XXeNirOdgJwkF5sOrU8GGnIOTxRlQdGMlp1aIUtGYIYBpp9DBoVmNHTZe96tVrcTMcvsE4Phgyqo7Jqr06rUUdk1Vrshl7uWJ5_K8LxqQmGzWOIzj0S1QVbdq27WSWb4oX99Kln9A82P-KPAuqVaCDjzHg8J8vkH9Q2qZT7Pm_2PEf7OuVxZzSncWgorboNBobUKe8RvtX_ifgVvFg
CitedBy_id crossref_primary_10_1002_advs_202410495
crossref_primary_10_3390_ijms26052103
crossref_primary_10_3389_fphar_2024_1510030
crossref_primary_10_1186_s12933_024_02368_y
crossref_primary_10_4330_wjc_v17_i1_101491
crossref_primary_10_3390_ijms251810225
crossref_primary_10_3390_ijms26041670
crossref_primary_10_1007_s11302_024_10045_8
crossref_primary_10_1016_j_cpcardiol_2024_102951
Cites_doi 10.1038/cmi.2017.20
10.1159/000159247
10.1016/j.atherosclerosis.2018.02.028
10.1056/NEJMoa1911303
10.1161/CIRCRESAHA.112.267237
10.3390/ijms22020818
10.1007/s00210-023-02627-x
10.1161/CIRCRESAHA.121.320251
10.3390/ijms151223501
10.1161/ATVBAHA.119.312659
10.1152/ajpendo.00053.2009
10.1093/cvr/cvad119
10.1146/annurev-physiol-031620-095920
10.1093/eurheartj/ehad192
10.1161/CIRCRESAHA.117.312130
10.1038/s41401-023-01217-0
10.1016/j.lfs.2020.117389
10.1136/gutjnl-2021-325065
10.1016/S0140-6736(18)32590-X
10.1186/s12933-019-0903-4
10.1038/s41588-019-0514-8
10.1038/s41467-020-18047-x
10.1186/s12933-018-0749-1
10.1172/JCI143645
10.1161/01.CIR.92.8.2029
10.1002/sim.3697
10.1007/s00210-023-02607-1
10.1093/eurheartj/ehad195
10.1056/NEJMoa1504720
10.1172/JCI117205
10.1161/ATVBAHA.120.313131
10.1093/cvr/cvad133
10.1161/CIRCRESAHA.121.319745
10.1126/sciadv.abl8096
10.1038/s41591-022-01703-8
10.1172/JCI116391
10.2131/jts.23.5_433
10.3390/ijms21062204
10.1161/JAHA.113.000238
10.2337/db20-0840
10.1016/j.tcm.2014.10.021
ContentType Journal Article
Copyright 2024 The Authors
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2024 The Authors
– notice: Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTOC
UNPAY
DOA
DOI 10.1016/j.redox.2024.103183
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Unpaywall for CDI: Periodical Content
Unpaywall
Directory of Open Access Journals (DOAJ)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2213-2317
ExternalDocumentID oai_doaj_org_article_7ad92036e98041eaad59dcffc14e70d7
10.1016/j.redox.2024.103183
38759418
10_1016_j_redox_2024_103183
S2213231724001617
Genre Journal Article
GroupedDBID 0R~
0SF
457
53G
5VS
6I.
AACTN
AAEDT
AAEDW
AAFTH
AAIKJ
AALRI
AAXUO
ABGSF
ABMAC
ACGFS
ADBBV
ADEZE
ADRAZ
ADUVX
AENEX
AEXQZ
AFTJW
AGHFR
AITUG
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
BAWUL
BCNDV
DIK
EBS
EJD
FDB
GROUPED_DOAJ
HYE
HZ~
IPNFZ
IXB
M48
MO0
M~E
NCXOZ
O-L
O9-
OK1
RIG
ROL
RPM
SSZ
AAYWO
AAYXX
ACVFH
ADCNI
ADVLN
AEUPX
AFJKZ
AFPUW
AIGII
AKBMS
AKYEP
APXCP
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTOC
UNPAY
ID FETCH-LOGICAL-c470t-2d0aa9a8a3bbb8d29aa75276921b8ea5ea4b4a2b3e8be96b3e9f40ca9bc472c83
IEDL.DBID M48
ISSN 2213-2317
IngestDate Fri Oct 03 12:53:40 EDT 2025
Sun Oct 26 03:03:53 EDT 2025
Thu Oct 02 03:55:26 EDT 2025
Mon Jul 21 06:02:07 EDT 2025
Thu Apr 24 23:07:37 EDT 2025
Tue Jul 01 00:47:13 EDT 2025
Tue Jun 18 08:51:25 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Vascular calcification
Thioredoxin domain containing 5
Sodium-glucose cotransporter 2 inhibitors
Runx2
Endoplasmic reticulum stress
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
cc-by-nc-nd
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c470t-2d0aa9a8a3bbb8d29aa75276921b8ea5ea4b4a2b3e8be96b3e9f40ca9bc472c83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-7943-1361
OpenAccessLink https://proxy.k.utb.cz/login?url=https://doi.org/10.1016/j.redox.2024.103183
PMID 38759418
PQID 3056667910
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_7ad92036e98041eaad59dcffc14e70d7
unpaywall_primary_10_1016_j_redox_2024_103183
proquest_miscellaneous_3056667910
pubmed_primary_38759418
crossref_primary_10_1016_j_redox_2024_103183
crossref_citationtrail_10_1016_j_redox_2024_103183
elsevier_sciencedirect_doi_10_1016_j_redox_2024_103183
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate July 2024
2024-07-00
2024-Jul
20240701
2024-07-01
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: July 2024
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Redox biology
PublicationTitleAlternate Redox Biol
PublicationYear 2024
Publisher Elsevier B.V
Elsevier
Publisher_xml – name: Elsevier B.V
– name: Elsevier
References Yang, Dai, Wu (bib34) 2022; 130
Watson, Bostrom, Ravindranath, Lam, Norton, Demer (bib4) 1994; 93
Zelniker, Wiviott, Raz (bib43) 2019; 393
Wang, Dong, Song, Zhang, Pan, Han (bib15) 2018; 15
Spertus, Birmingham, Nassif (bib8) 2022; 28
Bostrom, Watson, Horn, Wortham, Herman, Demer (bib3) 1993; 91
Austin (bib21) 2009; 28
Liu, Chen, Li (bib32) 2023; 119
Zinman, Wanner, Lachin (bib6) 2015; 373
Horna-Terron, Pradilla-Dieste, Sanchez-de-Diego, Osada (bib12) 2014; 15
Shih, Chen, Zhang (bib13) 2018; 122
Ortega, Collado, Selles (bib20) 2019; 39
Dai, Liu, Cheng (bib25) 2022; 130
Vallon, Verma (bib40) 2021; 83
Sun, Byon, Yuan (bib5) 2012; 111
McDonagh, Metra, Adamo (bib42) 2023; 44
Marx, Federici, Schutt (bib41) 2023; 44
Kluger, Tecson, Lee (bib27) 2019; 18
Lee, Yeh, Lee (bib38) 2020; 11
Campeau, Leask (bib11) 2024; 397
McMurray, Solomon, Inzucchi (bib7) 2019; 381
Al-Sharea, Murphy, Huggins, Hu, Goldberg, Nagareddy (bib22) 2018; 271
Leopold (bib1) 2015; 25
Yeh, Cheng, Lin (bib16) 2022; 8
Masuda, Miyazaki-Anzai, Levi, Ting, Miyazaki (bib33) 2013; 2
Chen, Zhao, Wu (bib24) 2020; 40
Lu, Lee, Hsieh, Hsu (bib29) 2023; 24
Nasiri-Ansari, Nikolopoulou, Papoutsi (bib36) 2021; 22
Malhotra, Mauer, Lino Cardenas (bib26) 2019; 51
Chen, Lan, Li (bib9) 2023; 119
Niederhoffer, Bobryshev, Lartaud-Idjouadiene, Giummelly, Atkinson (bib17) 1997; 34
Sun, Byon, Yuan (bib30) 2012; 111
Herrmann, Babic, Tolle, van der Giet, Schuchardt (bib18) 2020; 21
Demer (bib2) 1995; 92
Li, Chen, Sun, Yang, Jin, Liu (bib10) 2024; 45
Nasiri-Ansari, Dimitriadis, Agrogiannis (bib23) 2018; 17
Hung, Su, Chen (bib14) 2022; 71
Barata, Yoshida, Hokao, Maekawa (bib19) 1998; 23
Hewedy, Abdulmalek, Ghareeb, Habiba (bib28) 2024; 397
Shih, Lin, Fisch (bib35) 2021; 70
Alberti, Karamessinis, Peroulis (bib37) 2009; 297
Gomathi, Akshaya, Srinaath, Moorthi, Selvamurugan (bib31) 2020; 245
Chen, Jhao, Hung (bib39) 2021; 131
McDonagh (10.1016/j.redox.2024.103183_bib42) 2023; 44
Zinman (10.1016/j.redox.2024.103183_bib6) 2015; 373
Austin (10.1016/j.redox.2024.103183_bib21) 2009; 28
Barata (10.1016/j.redox.2024.103183_bib19) 1998; 23
Masuda (10.1016/j.redox.2024.103183_bib33) 2013; 2
Wang (10.1016/j.redox.2024.103183_bib15) 2018; 15
Demer (10.1016/j.redox.2024.103183_bib2) 1995; 92
Zelniker (10.1016/j.redox.2024.103183_bib43) 2019; 393
Sun (10.1016/j.redox.2024.103183_bib30) 2012; 111
Yang (10.1016/j.redox.2024.103183_bib34) 2022; 130
Marx (10.1016/j.redox.2024.103183_bib41) 2023; 44
Alberti (10.1016/j.redox.2024.103183_bib37) 2009; 297
Dai (10.1016/j.redox.2024.103183_bib25) 2022; 130
Bostrom (10.1016/j.redox.2024.103183_bib3) 1993; 91
Gomathi (10.1016/j.redox.2024.103183_bib31) 2020; 245
Vallon (10.1016/j.redox.2024.103183_bib40) 2021; 83
Yeh (10.1016/j.redox.2024.103183_bib16) 2022; 8
Chen (10.1016/j.redox.2024.103183_bib39) 2021; 131
Niederhoffer (10.1016/j.redox.2024.103183_bib17) 1997; 34
Lu (10.1016/j.redox.2024.103183_bib29) 2023; 24
Hewedy (10.1016/j.redox.2024.103183_bib28) 2024; 397
Horna-Terron (10.1016/j.redox.2024.103183_bib12) 2014; 15
Nasiri-Ansari (10.1016/j.redox.2024.103183_bib23) 2018; 17
Kluger (10.1016/j.redox.2024.103183_bib27) 2019; 18
Chen (10.1016/j.redox.2024.103183_bib9) 2023; 119
Chen (10.1016/j.redox.2024.103183_bib24) 2020; 40
Spertus (10.1016/j.redox.2024.103183_bib8) 2022; 28
Leopold (10.1016/j.redox.2024.103183_bib1) 2015; 25
McMurray (10.1016/j.redox.2024.103183_bib7) 2019; 381
Malhotra (10.1016/j.redox.2024.103183_bib26) 2019; 51
Lee (10.1016/j.redox.2024.103183_bib38) 2020; 11
Sun (10.1016/j.redox.2024.103183_bib5) 2012; 111
Liu (10.1016/j.redox.2024.103183_bib32) 2023; 119
Shih (10.1016/j.redox.2024.103183_bib13) 2018; 122
Ortega (10.1016/j.redox.2024.103183_bib20) 2019; 39
Campeau (10.1016/j.redox.2024.103183_bib11) 2024; 397
Herrmann (10.1016/j.redox.2024.103183_bib18) 2020; 21
Nasiri-Ansari (10.1016/j.redox.2024.103183_bib36) 2021; 22
Watson (10.1016/j.redox.2024.103183_bib4) 1994; 93
Hung (10.1016/j.redox.2024.103183_bib14) 2022; 71
Al-Sharea (10.1016/j.redox.2024.103183_bib22) 2018; 271
Li (10.1016/j.redox.2024.103183_bib10) 2024; 45
Shih (10.1016/j.redox.2024.103183_bib35) 2021; 70
References_xml – volume: 51
  start-page: 1580
  year: 2019
  end-page: 1587
  ident: bib26
  article-title: HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype
  publication-title: Nat. Genet.
– volume: 245
  year: 2020
  ident: bib31
  article-title: Regulation of Runx2 by post-translational modifications in osteoblast differentiation
  publication-title: Life Sci.
– volume: 28
  start-page: 809
  year: 2022
  end-page: 813
  ident: bib8
  article-title: The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
  publication-title: Nat. Med.
– volume: 297
  start-page: E812
  year: 2009
  end-page: E821
  ident: bib37
  article-title: ERp46 is reduced by high glucose and regulates insulin content in pancreatic beta-cells
  publication-title: Am. J. Physiol. Endocrinol. Metab.
– volume: 91
  start-page: 1800
  year: 1993
  end-page: 1809
  ident: bib3
  article-title: Bone morphogenetic protein expression in human atherosclerotic lesions
  publication-title: J. Clin. Invest.
– volume: 44
  start-page: 4043
  year: 2023
  end-page: 4140
  ident: bib41
  article-title: ESC Guidelines for the management of cardiovascular disease in patients with diabetes
  publication-title: Eur. Heart J.
– volume: 381
  start-page: 1995
  year: 2019
  end-page: 2008
  ident: bib7
  article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction
  publication-title: N. Engl. J. Med.
– volume: 22
  start-page: 818
  year: 2021
  ident: bib36
  article-title: Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE((-/-)) mice by activating autophagy and reducing ER stress and apoptosis
  publication-title: Int. J. Mol. Sci.
– volume: 393
  start-page: 31
  year: 2019
  end-page: 39
  ident: bib43
  article-title: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
  publication-title: Lancet
– volume: 111
  start-page: 543
  year: 2012
  end-page: 552
  ident: bib5
  article-title: Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification
  publication-title: Circ. Res.
– volume: 122
  start-page: 1052
  year: 2018
  end-page: 1068
  ident: bib13
  article-title: Endoplasmic reticulum protein TXNDC5 augments myocardial fibrosis by facilitating extracellular matrix protein folding and redox-sensitive cardiac fibroblast activation
  publication-title: Circ. Res.
– volume: 15
  start-page: 685
  year: 2018
  end-page: 696
  ident: bib15
  article-title: TXNDC5 synergizes with HSC70 to exacerbate the inflammatory phenotype of synovial fibroblasts in rheumatoid arthritis through NF-kappaB signaling
  publication-title: Cell. Mol. Immunol.
– volume: 45
  start-page: 751
  year: 2024
  end-page: 764
  ident: bib10
  article-title: Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation
  publication-title: Acta Pharmacol. Sin.
– volume: 23
  start-page: 433
  year: 1998
  end-page: 442
  ident: bib19
  article-title: Sequential alterations in clinical biochemical indicators of renal function in 5/6 nephrectomized rats--basic study for renal toxicity using 5/6 nephrectomized rats
  publication-title: J. Toxicol. Sci.
– volume: 28
  start-page: 3083
  year: 2009
  end-page: 3107
  ident: bib21
  article-title: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
  publication-title: Stat. Med.
– volume: 111
  start-page: 543
  year: 2012
  end-page: 552
  ident: bib30
  article-title: Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification
  publication-title: Circ. Res.
– volume: 21
  start-page: 2204
  year: 2020
  ident: bib18
  article-title: Research models for studying vascular calcification
  publication-title: Int. J. Mol. Sci.
– volume: 130
  start-page: 1565
  year: 2022
  end-page: 1582
  ident: bib25
  article-title: Epigenetic upregulation of H19 and AMPK inhibition concurrently contribute to S-adenosylhomocysteine hydrolase deficiency-promoted atherosclerotic calcification
  publication-title: Circ. Res.
– volume: 93
  start-page: 2106
  year: 1994
  end-page: 2113
  ident: bib4
  article-title: TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify
  publication-title: J. Clin. Invest.
– volume: 18
  start-page: 99
  year: 2019
  ident: bib27
  article-title: Class effects of SGLT2 inhibitors on cardiorenal outcomes
  publication-title: Cardiovasc. Diabetol.
– volume: 39
  start-page: 1614
  year: 2019
  end-page: 1628
  ident: bib20
  article-title: SGLT-2 (Sodium-Glucose cotransporter 2) inhibition reduces ang II (angiotensin II)-Induced dissecting abdominal aortic aneurysm in ApoE (apolipoprotein E) knockout mice
  publication-title: Arterioscler. Thromb. Vasc. Biol.
– volume: 34
  start-page: 386
  year: 1997
  end-page: 398
  ident: bib17
  article-title: Aortic calcification produced by vitamin D3 plus nicotine
  publication-title: J. Vasc. Res.
– volume: 17
  start-page: 106
  year: 2018
  ident: bib23
  article-title: Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
  publication-title: Cardiovasc. Diabetol.
– volume: 397
  start-page: 873
  year: 2024
  end-page: 888
  ident: bib28
  article-title: AMPK-mediated autophagy is involved in the protective effect of canagliflozin in the vitamin D3 plus nicotine calcification model in rats
  publication-title: Naunyn-Schmiedeberg’s Arch. Pharmacol.
– volume: 373
  start-page: 2117
  year: 2015
  end-page: 2128
  ident: bib6
  article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
  publication-title: N. Engl. J. Med.
– volume: 71
  start-page: 1876
  year: 2022
  end-page: 1891
  ident: bib14
  article-title: Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling
  publication-title: Gut
– volume: 131
  year: 2021
  ident: bib39
  article-title: Endoplasmic reticulum protein TXNDC5 promotes renal fibrosis by enforcing TGF-beta signaling in kidney fibroblasts
  publication-title: J. Clin. Invest.
– volume: 83
  start-page: 503
  year: 2021
  end-page: 528
  ident: bib40
  article-title: Effects of SGLT2 inhibitors on kidney and cardiovascular function
  publication-title: Annu. Rev. Physiol.
– volume: 15
  start-page: 23501
  year: 2014
  end-page: 23518
  ident: bib12
  article-title: TXNDC5, a newly discovered disulfide isomerase with a key role in cell physiology and pathology
  publication-title: Int. J. Mol. Sci.
– volume: 92
  start-page: 2029
  year: 1995
  end-page: 2032
  ident: bib2
  article-title: A skeleton in the atherosclerosis closet
  publication-title: Circulation
– volume: 24
  year: 2023
  ident: bib29
  article-title: Empagliflozin attenuates vascular calcification in mice with chronic kidney disease by regulating the NFR2/HO-1 anti-inflammatory pathway through AMPK activation
  publication-title: Int. J. Mol. Sci.
– volume: 40
  start-page: 1078
  year: 2020
  end-page: 1093
  ident: bib24
  article-title: Arterial stiffness: a focus on vascular calcification and its link to bone mineralization
  publication-title: Arterioscler. Thromb. Vasc. Biol.
– volume: 25
  start-page: 267
  year: 2015
  end-page: 274
  ident: bib1
  article-title: Vascular calcification: mechanisms of vascular smooth muscle cell calcification
  publication-title: Trends Cardiovasc. Med.
– volume: 130
  start-page: 213
  year: 2022
  end-page: 229
  ident: bib34
  article-title: Unspliced XBP1 counteracts beta-catenin to inhibit vascular calcification
  publication-title: Circ. Res.
– volume: 8
  year: 2022
  ident: bib16
  article-title: Targeting mechanosensitive endothelial TXNDC5 to stabilize eNOS and reduce atherosclerosis in vivo
  publication-title: Sci. Adv.
– volume: 119
  start-page: 2563
  year: 2023
  end-page: 2578
  ident: bib32
  article-title: C5a-C5aR1 induces endoplasmic reticulum stress to accelerate vascular calcification via PERK-eIF2alpha-ATF4-CREB3L1 pathway
  publication-title: Cardiovasc. Res.
– volume: 44
  start-page: 3627
  year: 2023
  end-page: 3639
  ident: bib42
  article-title: Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
  publication-title: Eur. Heart J.
– volume: 11
  start-page: 4254
  year: 2020
  ident: bib38
  article-title: Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFbeta signaling through TGFBR1 stabilization
  publication-title: Nat. Commun.
– volume: 271
  start-page: 166
  year: 2018
  end-page: 176
  ident: bib22
  article-title: SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-/-) type 1 diabetic mice
  publication-title: Atherosclerosis
– volume: 2
  year: 2013
  ident: bib33
  article-title: PERK-eIF2alpha-ATF4-CHOP signaling contributes to TNFalpha-induced vascular calcification
  publication-title: J. Am. Heart Assoc.
– volume: 119
  start-page: 2368
  year: 2023
  end-page: 2381
  ident: bib9
  article-title: Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome
  publication-title: Cardiovasc. Res.
– volume: 70
  start-page: 262
  year: 2021
  end-page: 267
  ident: bib35
  article-title: Dapagliflozin suppresses ER stress and improves subclinical myocardial function in diabetes: from bedside to bench
  publication-title: Diabetes
– volume: 397
  start-page: 267
  year: 2024
  end-page: 279
  ident: bib11
  article-title: Empagliflozin reduces endoplasmic reticulum stress associated TXNIP/NLRP3 activation in tunicamycin-stimulated aortic endothelial cells
  publication-title: Naunyn-Schmiedeberg’s Arch. Pharmacol.
– volume: 15
  start-page: 685
  year: 2018
  ident: 10.1016/j.redox.2024.103183_bib15
  article-title: TXNDC5 synergizes with HSC70 to exacerbate the inflammatory phenotype of synovial fibroblasts in rheumatoid arthritis through NF-kappaB signaling
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/cmi.2017.20
– volume: 34
  start-page: 386
  year: 1997
  ident: 10.1016/j.redox.2024.103183_bib17
  article-title: Aortic calcification produced by vitamin D3 plus nicotine
  publication-title: J. Vasc. Res.
  doi: 10.1159/000159247
– volume: 271
  start-page: 166
  year: 2018
  ident: 10.1016/j.redox.2024.103183_bib22
  article-title: SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-/-) type 1 diabetic mice
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2018.02.028
– volume: 381
  start-page: 1995
  year: 2019
  ident: 10.1016/j.redox.2024.103183_bib7
  article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1911303
– volume: 111
  start-page: 543
  year: 2012
  ident: 10.1016/j.redox.2024.103183_bib5
  article-title: Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification
  publication-title: Circ. Res.
  doi: 10.1161/CIRCRESAHA.112.267237
– volume: 22
  start-page: 818
  year: 2021
  ident: 10.1016/j.redox.2024.103183_bib36
  article-title: Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE((-/-)) mice by activating autophagy and reducing ER stress and apoptosis
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms22020818
– volume: 397
  start-page: 873
  year: 2024
  ident: 10.1016/j.redox.2024.103183_bib28
  article-title: AMPK-mediated autophagy is involved in the protective effect of canagliflozin in the vitamin D3 plus nicotine calcification model in rats
  publication-title: Naunyn-Schmiedeberg’s Arch. Pharmacol.
  doi: 10.1007/s00210-023-02627-x
– volume: 130
  start-page: 1565
  year: 2022
  ident: 10.1016/j.redox.2024.103183_bib25
  article-title: Epigenetic upregulation of H19 and AMPK inhibition concurrently contribute to S-adenosylhomocysteine hydrolase deficiency-promoted atherosclerotic calcification
  publication-title: Circ. Res.
  doi: 10.1161/CIRCRESAHA.121.320251
– volume: 15
  start-page: 23501
  year: 2014
  ident: 10.1016/j.redox.2024.103183_bib12
  article-title: TXNDC5, a newly discovered disulfide isomerase with a key role in cell physiology and pathology
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms151223501
– volume: 39
  start-page: 1614
  year: 2019
  ident: 10.1016/j.redox.2024.103183_bib20
  article-title: SGLT-2 (Sodium-Glucose cotransporter 2) inhibition reduces ang II (angiotensin II)-Induced dissecting abdominal aortic aneurysm in ApoE (apolipoprotein E) knockout mice
  publication-title: Arterioscler. Thromb. Vasc. Biol.
  doi: 10.1161/ATVBAHA.119.312659
– volume: 297
  start-page: E812
  year: 2009
  ident: 10.1016/j.redox.2024.103183_bib37
  article-title: ERp46 is reduced by high glucose and regulates insulin content in pancreatic beta-cells
  publication-title: Am. J. Physiol. Endocrinol. Metab.
  doi: 10.1152/ajpendo.00053.2009
– volume: 119
  start-page: 2368
  year: 2023
  ident: 10.1016/j.redox.2024.103183_bib9
  article-title: Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome
  publication-title: Cardiovasc. Res.
  doi: 10.1093/cvr/cvad119
– volume: 83
  start-page: 503
  year: 2021
  ident: 10.1016/j.redox.2024.103183_bib40
  article-title: Effects of SGLT2 inhibitors on kidney and cardiovascular function
  publication-title: Annu. Rev. Physiol.
  doi: 10.1146/annurev-physiol-031620-095920
– volume: 44
  start-page: 4043
  year: 2023
  ident: 10.1016/j.redox.2024.103183_bib41
  article-title: ESC Guidelines for the management of cardiovascular disease in patients with diabetes
  publication-title: Eur. Heart J.
  doi: 10.1093/eurheartj/ehad192
– volume: 122
  start-page: 1052
  year: 2018
  ident: 10.1016/j.redox.2024.103183_bib13
  article-title: Endoplasmic reticulum protein TXNDC5 augments myocardial fibrosis by facilitating extracellular matrix protein folding and redox-sensitive cardiac fibroblast activation
  publication-title: Circ. Res.
  doi: 10.1161/CIRCRESAHA.117.312130
– volume: 45
  start-page: 751
  year: 2024
  ident: 10.1016/j.redox.2024.103183_bib10
  article-title: Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation
  publication-title: Acta Pharmacol. Sin.
  doi: 10.1038/s41401-023-01217-0
– volume: 245
  year: 2020
  ident: 10.1016/j.redox.2024.103183_bib31
  article-title: Regulation of Runx2 by post-translational modifications in osteoblast differentiation
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2020.117389
– volume: 71
  start-page: 1876
  year: 2022
  ident: 10.1016/j.redox.2024.103183_bib14
  article-title: Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling
  publication-title: Gut
  doi: 10.1136/gutjnl-2021-325065
– volume: 393
  start-page: 31
  year: 2019
  ident: 10.1016/j.redox.2024.103183_bib43
  article-title: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)32590-X
– volume: 18
  start-page: 99
  year: 2019
  ident: 10.1016/j.redox.2024.103183_bib27
  article-title: Class effects of SGLT2 inhibitors on cardiorenal outcomes
  publication-title: Cardiovasc. Diabetol.
  doi: 10.1186/s12933-019-0903-4
– volume: 51
  start-page: 1580
  year: 2019
  ident: 10.1016/j.redox.2024.103183_bib26
  article-title: HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-019-0514-8
– volume: 11
  start-page: 4254
  year: 2020
  ident: 10.1016/j.redox.2024.103183_bib38
  article-title: Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFbeta signaling through TGFBR1 stabilization
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18047-x
– volume: 17
  start-page: 106
  year: 2018
  ident: 10.1016/j.redox.2024.103183_bib23
  article-title: Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
  publication-title: Cardiovasc. Diabetol.
  doi: 10.1186/s12933-018-0749-1
– volume: 131
  year: 2021
  ident: 10.1016/j.redox.2024.103183_bib39
  article-title: Endoplasmic reticulum protein TXNDC5 promotes renal fibrosis by enforcing TGF-beta signaling in kidney fibroblasts
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI143645
– volume: 92
  start-page: 2029
  year: 1995
  ident: 10.1016/j.redox.2024.103183_bib2
  article-title: A skeleton in the atherosclerosis closet
  publication-title: Circulation
  doi: 10.1161/01.CIR.92.8.2029
– volume: 28
  start-page: 3083
  year: 2009
  ident: 10.1016/j.redox.2024.103183_bib21
  article-title: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
  publication-title: Stat. Med.
  doi: 10.1002/sim.3697
– volume: 397
  start-page: 267
  year: 2024
  ident: 10.1016/j.redox.2024.103183_bib11
  article-title: Empagliflozin reduces endoplasmic reticulum stress associated TXNIP/NLRP3 activation in tunicamycin-stimulated aortic endothelial cells
  publication-title: Naunyn-Schmiedeberg’s Arch. Pharmacol.
  doi: 10.1007/s00210-023-02607-1
– volume: 44
  start-page: 3627
  year: 2023
  ident: 10.1016/j.redox.2024.103183_bib42
  article-title: Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
  publication-title: Eur. Heart J.
  doi: 10.1093/eurheartj/ehad195
– volume: 373
  start-page: 2117
  year: 2015
  ident: 10.1016/j.redox.2024.103183_bib6
  article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1504720
– volume: 111
  start-page: 543
  year: 2012
  ident: 10.1016/j.redox.2024.103183_bib30
  article-title: Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification
  publication-title: Circ. Res.
  doi: 10.1161/CIRCRESAHA.112.267237
– volume: 93
  start-page: 2106
  year: 1994
  ident: 10.1016/j.redox.2024.103183_bib4
  article-title: TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI117205
– volume: 40
  start-page: 1078
  year: 2020
  ident: 10.1016/j.redox.2024.103183_bib24
  article-title: Arterial stiffness: a focus on vascular calcification and its link to bone mineralization
  publication-title: Arterioscler. Thromb. Vasc. Biol.
  doi: 10.1161/ATVBAHA.120.313131
– volume: 119
  start-page: 2563
  year: 2023
  ident: 10.1016/j.redox.2024.103183_bib32
  article-title: C5a-C5aR1 induces endoplasmic reticulum stress to accelerate vascular calcification via PERK-eIF2alpha-ATF4-CREB3L1 pathway
  publication-title: Cardiovasc. Res.
  doi: 10.1093/cvr/cvad133
– volume: 130
  start-page: 213
  year: 2022
  ident: 10.1016/j.redox.2024.103183_bib34
  article-title: Unspliced XBP1 counteracts beta-catenin to inhibit vascular calcification
  publication-title: Circ. Res.
  doi: 10.1161/CIRCRESAHA.121.319745
– volume: 8
  year: 2022
  ident: 10.1016/j.redox.2024.103183_bib16
  article-title: Targeting mechanosensitive endothelial TXNDC5 to stabilize eNOS and reduce atherosclerosis in vivo
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abl8096
– volume: 28
  start-page: 809
  year: 2022
  ident: 10.1016/j.redox.2024.103183_bib8
  article-title: The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01703-8
– volume: 91
  start-page: 1800
  year: 1993
  ident: 10.1016/j.redox.2024.103183_bib3
  article-title: Bone morphogenetic protein expression in human atherosclerotic lesions
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI116391
– volume: 24
  year: 2023
  ident: 10.1016/j.redox.2024.103183_bib29
  article-title: Empagliflozin attenuates vascular calcification in mice with chronic kidney disease by regulating the NFR2/HO-1 anti-inflammatory pathway through AMPK activation
  publication-title: Int. J. Mol. Sci.
– volume: 23
  start-page: 433
  year: 1998
  ident: 10.1016/j.redox.2024.103183_bib19
  article-title: Sequential alterations in clinical biochemical indicators of renal function in 5/6 nephrectomized rats--basic study for renal toxicity using 5/6 nephrectomized rats
  publication-title: J. Toxicol. Sci.
  doi: 10.2131/jts.23.5_433
– volume: 21
  start-page: 2204
  year: 2020
  ident: 10.1016/j.redox.2024.103183_bib18
  article-title: Research models for studying vascular calcification
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21062204
– volume: 2
  year: 2013
  ident: 10.1016/j.redox.2024.103183_bib33
  article-title: PERK-eIF2alpha-ATF4-CHOP signaling contributes to TNFalpha-induced vascular calcification
  publication-title: J. Am. Heart Assoc.
  doi: 10.1161/JAHA.113.000238
– volume: 70
  start-page: 262
  year: 2021
  ident: 10.1016/j.redox.2024.103183_bib35
  article-title: Dapagliflozin suppresses ER stress and improves subclinical myocardial function in diabetes: from bedside to bench
  publication-title: Diabetes
  doi: 10.2337/db20-0840
– volume: 25
  start-page: 267
  year: 2015
  ident: 10.1016/j.redox.2024.103183_bib1
  article-title: Vascular calcification: mechanisms of vascular smooth muscle cell calcification
  publication-title: Trends Cardiovasc. Med.
  doi: 10.1016/j.tcm.2014.10.021
SSID ssj0000884210
Score 2.4168806
Snippet Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose...
Aims: Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose...
SourceID doaj
unpaywall
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 103183
SubjectTerms Animals
Benzhydryl Compounds - pharmacology
Core Binding Factor Alpha 1 Subunit - genetics
Core Binding Factor Alpha 1 Subunit - metabolism
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Disease Models, Animal
Endoplasmic Reticulum - drug effects
Endoplasmic Reticulum - metabolism
Endoplasmic reticulum stress
Endoplasmic Reticulum Stress - drug effects
Female
Glucosides - pharmacology
Humans
Male
Mice
Muscle, Smooth, Vascular - cytology
Muscle, Smooth, Vascular - drug effects
Muscle, Smooth, Vascular - metabolism
Muscle, Smooth, Vascular - pathology
Myocytes, Smooth Muscle - drug effects
Myocytes, Smooth Muscle - metabolism
Osteogenesis - drug effects
Rats
Runx2
Sodium-glucose cotransporter 2 inhibitors
Sodium-Glucose Transporter 2 Inhibitors - pharmacology
Thioredoxin domain containing 5
Thioredoxins - genetics
Thioredoxins - metabolism
Vascular calcification
Vascular Calcification - drug therapy
Vascular Calcification - etiology
Vascular Calcification - metabolism
Vascular Calcification - pathology
SummonAdditionalLinks – databaseName: Directory of Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQJQQcEN-kFGQkjkQkjpPYx1JRVUhwgUq9WePYoUG7zqpNBPvX-us6tpNoK6TCgVNWK8cb77ys32zevCHkHTe2LjCcKfPiMA55m4LVVdqWmS7yUhem9IXCX75WJ6f881l5ttPqy2vCoj1w_OI-1GCkf1hmpXfKsQCmlKZp2ybnts5MqCPPhNxJpsJvsBAck5nZZigIurwB52_MCBn3lea5KG5sRcGx_8aO9CfjfEDujW4D21-wWu3sQsePyMOJPtLDeNmPyR3rnpC7saHk9im5-tabblzPQnTa9MNiXn5BGe3ceac732CHel9NNyLTpLMYlWK4gkIvBIvqLb0cN1En635Q60y_Qaq97hoaKh_934Y02Dx0jg7nXR9Wjq9NvwY8eBF8bD9BSzr32h2oLyrpEbVhmkkdtsZBz8jp8afvRyfp1J0hbXidDSkzGYAEAYXWWhgmAeqS1ZVkuRYWSgtcc2C6sEJbWeFRtjxrQGo8nzWieE72XO_sS0JFiyQQwyWBCy5wWoEh1pWFrNJt09qEsDlQqpmsy30HjZWaNWo_VVij8tFVMboJeb-ctInOHbcP_-gRsAz1ttvhDQSjmsCo_gbGhFQzftTEYCIzwam62z_97Yw2hfe3f2gDzvbjpfIpXlXVyOoS8iLCcLnGApNNyXORkHTB5b-sdf9_rPUVue-njNLlA7I3XIz2NRK0Qb8J9-I14l9AvA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ScienceDirect Free & Delayed Access Titles
  dbid: IXB
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhUNoeSt_Z9IEKPdasLcu2dGxCQ1poL2lgb2ZkyYnLrm02Ns3-tf66zsgPuhRC6Um2kGTJM5JG9jffMPZeWpfFKM5AEDhMQlQG4EwalElo4igxsU3IUfjrt_T8Un5ZJasDdjr5whCsclz7hzXdr9ZjznJ8m8u2qpYXQuBJCrc_QkGSlY7rcCwVhW_4vDqZv7PgLJLCkxJQ-YAqTORDHuZFtJy3eE4UkvzPIxXvbVCex39vn_rbDn3I7vd1C7ufsF7_sTedPWaPRqOSfxz6_YQduPopuzeEmdw9Y78uGlv1mwmezoummynNt1zwqr6uTEVhdzixbdY92p98gqhyFKLH7XkRcrPjN307oGfrK-5q27RogG-qgnt_SPqYyD35Q1Xz7rpq_Mjx2jYbwISg8UNQCp7wKQJvx8nVpEFd9s2MmLENFnrOLs8-fT89D8aYDUEhs7ALhA0BNCiIjTHKCg2QJSJLtYiMcpA4kEaCMLFTxukUU13KsABtsL4oVPyCHdZN7Y4YVyWahig6DVKhXAGUtoVJHYSpKYvSLZiYBJUXI6E5xdVY5xNy7Ufux5iTdPNBugv2Ya7UDnwedxc_IQ2YixIZt89otlf5qI15BlbT_1yniczJAdgEe1qWRSRdFtpswdJJf_I93camqruf_m7SthxnPf3Kgdo1_U1OB780zdDWW7CXgxrOfYzxCKplpBYsmPXyX8Z6_L_dfMUe0N0AYn7NDrtt796gqdaZt34u_gYejUJH
  priority: 102
  providerName: Elsevier
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFA46i4gP3i8VlQg-2qVN0zR5XMVlEVwEHVifysmlbnWmHXZadsef5q_zJG0HR2VZn1pKkiac0-RL853vEPKKW1dkaM6YeXIYh7SKwWkRV3miszTXmc19oPCHY3E05-9P8pNRZ9vHwuyc3wceltfNvMCNHOM-QBw98DrZEzkC7xnZmx9_PPji08exNIsRqRSTrtC_a-6sPUGif2cJ-hti3iI3-2YFm3NYLH5bdg7vDPHc66BW6Nkm3_f7Tu-bH39oOV5xRHfJ7RF-0oPBX-6Ra665T24MCSk3D8jPT62t--VEZKem7bbi52eU0bo5rXXtE_RQr8vZ9IhU6URmpWjuwPALxqZ6Q9f9auDZNl-pa2y7Qqi-rA0NkZP-tyMNMhF1Q7vTug0dxnvbLgEvnkQ_pK-gOZ1y9XbUB6W06PWhmZFdtsRCD8n88N3nt0fxmN0hNrxIupjZBECBhExrLS1TAEXOCqFYqqWD3AHXHJjOnNROCbyqiicGlMb6zMjsEZk1beOeECorBJG4d1XAJZfYrFTWaOEgEboylYsIm-xemlH63GfgWJQTx-1bGcZYeqOUg1Ei8npbaTUof1xe_I13qG1RL9sdHqDty3EWKAuwyp_8OuVlnxyAzbGnVWVS7orEFhERkzuWIwIakA02VV_-9peT85Y4P_hDH2hc269Lv0UUokBUGJHHg1dv-5jhZlXxVEYk3rr5Vcb69D_LPyOz7qx3zxG-dfrF-Nn-AtdXSag
  priority: 102
  providerName: Unpaywall
Title Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming
URI https://dx.doi.org/10.1016/j.redox.2024.103183
https://www.ncbi.nlm.nih.gov/pubmed/38759418
https://www.proquest.com/docview/3056667910
https://doi.org/10.1016/j.redox.2024.103183
https://doaj.org/article/7ad92036e98041eaad59dcffc14e70d7
UnpaywallVersion publishedVersion
Volume 73
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2213-2317
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884210
  issn: 2213-2317
  databaseCode: DOA
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVESC
  databaseName: ScienceDirect Free & Delayed Access Titles
  customDbUrl:
  eissn: 2213-2317
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884210
  issn: 2213-2317
  databaseCode: IXB
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2213-2317
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884210
  issn: 2213-2317
  databaseCode: DIK
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2213-2317
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884210
  issn: 2213-2317
  databaseCode: M~E
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 2213-2317
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884210
  issn: 2213-2317
  databaseCode: AKRWK
  dateStart: 20130101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2213-2317
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000884210
  issn: 2213-2317
  databaseCode: RPM
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal - Open Access
  customDbUrl:
  eissn: 2213-2317
  dateEnd: 20250831
  omitProxy: true
  ssIdentifier: ssj0000884210
  issn: 2213-2317
  databaseCode: M48
  dateStart: 20130201
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1db9MwFL0am4DxgPgc4aMyEo8EpYmT2A8IbYhpIG1CgkrlKbJjZwtqk65NxPrX-HXc6yRliDHxkkSV7Sa51_FxcnwOwCtubBphOP2QyGFcjQtfWZ34RRzoaBzryMS0UPj4JDma8E_TeLoFgytqfwNXV07tyE9qspy9uThfv8MO__Y3V4u0NS9wshdyWkSOWXoDdnCokuTlcNzjffdoFoLjHGdQH7q67i7cihDFS05GIJcGK6fp_8eY9TcmvQO322qh1j_UbHZpnDq8B3d7gMn2u4y4D1u2egA3O8vJ9UP4-aU2ZTsfqOosr5uNvPmShayszkpdkgUPI-XNqkUsyga6KsOAOg6fCyfTa7ZqFx2TtjpltjL1AsH4vMyZWxtJLxaZE4IoK9aclbW7CXhs6rnCHdHkO4MKFrPBjbdhtOykxrx2zfT8sTkWegSTww9f3x_5vX-Dn_M0aPzQBEpJJVSktRYmlEqlcZgmMhxrYVVsFddchTqyQluZ4F4WPMiV1Fg_zEX0GLarurJPgIkCYSJGTiouuMBmhTS5TqwKEl3khfUgHAKV5b24OXlszLKBxfY9c9eYUaCzLtAevN5UWnTaHtcXP6AM2BQlYW73Q708zfp-nqXKSPq2ayUJO1mlTIxnWhT5mNs0MKkHyZA_WY9xOuyCTZXX__vLIdsyfALQZx1V2bpdZTQJTJIUcZ8He10abs5xSGQP_E1e_s-1Pv1nS89gl8p1jOXnsN0sW_sCcVmjR-59Bm4_Tg9Grt-NYGdy8nn_2y_Z3j9V
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGENp4QNzGytVIPBI1cZzEfmQTU4FtL9ukvll27GxBbVJ1iaB_jV_HOc5FVEgT4ilVart2z7H9OfnOdwj5wK3LYjBnwJAcxnVUBNqZNCiS0MRRYmKbYKDw2Xk6u-Jf58l8hxwPsTBIq-zX_m5N96t1f2fa_5vTVVlOLxiDkxRsf8iCRJR-j9znCaATjOKbH40PWmAaceZVCbBCgDUG9SHP80Jdzp9wUGQcA9AjEW_tUF7If2uj-huIPiR7bbXSmx96sfhjczp5TB71qJJ-6jr-hOy46il50OWZ3Dwjvy5qW7bLgZ9O87oZNc3XlNGyuilNiXl3KMptVi0AUDpwVClY0RP3vA2p2dDbdtXRZ6tr6ipbrwCBL8uc-oBIfJpIvfpDWdHmpqz9yOGzrZcaLsiN77JS0IQOKXgbirEmNTizb6YnjS2h0HNydfL58ngW9EkbgpxnYRMwG2ottdCxMUZYJrXOEpalkkVGOJ04zQ3XzMROGCdTuMqCh7mWBuqzXMQHZLeqK3dIqCgAG4LppOaCC2hWSJub1OkwNUVeuAlhg6FU3iuaY2KNhRqoa9-VH6NC66rOuhPycay06gQ97i5-hB4wFkU1bn-jXl-r3h1Vpq3EF7pOopqT09om0NOiyCPustBmE5IO_qO2nBuaKu_-9feDtymY9vguR1eubm8VnvzSNAOwNyEvOjcc-xjDGVTySExIMPrlv4z15f928x3Zm12enarTL-ffXpF9_KZjNL8mu826dW8AtzXmrZ-XvwFX90Vt
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFA46i4gP3i8VlQg-2qVN0zR5XMVlEVwEHVifysmlbnWmHXZadsef5q_zJG0HR2VZn1pKkiac0-RL853vEPKKW1dkaM6YeXIYh7SKwWkRV3miszTXmc19oPCHY3E05-9P8pNRZ9vHwuyc3wceltfNvMCNHOM-QBw98DrZEzkC7xnZmx9_PPji08exNIsRqRSTrtC_a-6sPUGif2cJ-hti3iI3-2YFm3NYLH5bdg7vDPHc66BW6Nkm3_f7Tu-bH39oOV5xRHfJ7RF-0oPBX-6Ra665T24MCSk3D8jPT62t--VEZKem7bbi52eU0bo5rXXtE_RQr8vZ9IhU6URmpWjuwPALxqZ6Q9f9auDZNl-pa2y7Qqi-rA0NkZP-tyMNMhF1Q7vTug0dxnvbLgEvnkQ_pK-gOZ1y9XbUB6W06PWhmZFdtsRCD8n88N3nt0fxmN0hNrxIupjZBECBhExrLS1TAEXOCqFYqqWD3AHXHJjOnNROCbyqiicGlMb6zMjsEZk1beOeECorBJG4d1XAJZfYrFTWaOEgEboylYsIm-xemlH63GfgWJQTx-1bGcZYeqOUg1Ei8npbaTUof1xe_I13qG1RL9sdHqDty3EWKAuwyp_8OuVlnxyAzbGnVWVS7orEFhERkzuWIwIakA02VV_-9peT85Y4P_hDH2hc269Lv0UUokBUGJHHg1dv-5jhZlXxVEYk3rr5Vcb69D_LPyOz7qx3zxG-dfrF-Nn-AtdXSag
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sodium-glucose+cotransporter+2+inhibitors+attenuate+vascular+calcification+by+suppressing+endoplasmic+reticulum+protein+thioredoxin+domain+containing+5+dependent+osteogenic+reprogramming&rft.jtitle=Redox+biology&rft.au=Wu%2C+Shaofa&rft.au=Luo%2C+Xiaolin&rft.au=Chen%2C+Yang&rft.au=Wang%2C+Zelan&rft.date=2024-07-01&rft.eissn=2213-2317&rft.volume=73&rft.spage=103183&rft_id=info:doi/10.1016%2Fj.redox.2024.103183&rft_id=info%3Apmid%2F38759418&rft.externalDocID=38759418
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2213-2317&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2213-2317&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2213-2317&client=summon